悦心健康(002162) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥186,519,515.45, a decrease of 10.67% compared to ¥208,808,508.79 in the same period last year[3] - The net profit attributable to shareholders was -¥15,294,690.85, representing a decline of 32.62% from -¥11,532,792.93 year-on-year[3] - The company reported a net loss of ¥60,520,947.43 for Q1 2022, compared to a loss of ¥45,226,256.58 in the previous year[23] - The net profit for Q1 2022 was -15,314,285.60 CNY, compared to -11,921,556.76 CNY in Q1 2021, representing an increase in net loss of approximately 28.5%[26] - Operating profit for Q1 2022 was -18,651,521.36 CNY, worsening from -11,527,694.29 CNY in the same period last year, indicating a decline of about 62.5%[26] - The company reported a total comprehensive loss of -9,090,560.83 CNY for Q1 2022, compared to -11,921,556.76 CNY in Q1 2021, showing an improvement in comprehensive loss by approximately 24.0%[27] Cash Flow - The net cash flow from operating activities was -¥98,177,017.43, a significant decrease of 181.90% compared to -¥34,827,113.90 in the previous year[14] - The net cash flow from operating activities for Q1 2022 was -98,177,017.43 CNY, compared to -34,827,113.90 CNY in Q1 2021, indicating a significant increase in cash outflow[30] - The company’s cash flow from investing activities was -¥13,895,417.28, an increase of 87.20% compared to -¥7,422,672.77 in the previous year[14] - Investment activities resulted in a net cash outflow of -13,895,417.28 CNY in Q1 2022, compared to -7,422,672.77 CNY in Q1 2021, indicating a worsening in investment cash flow[30] - The company received cash inflows from investment activities totaling 102,698,043.92 CNY in Q1 2022, significantly higher than 25,686,961.80 CNY in Q1 2021, reflecting a growth of approximately 299.5%[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,640,273,978.12, down 2.67% from ¥2,712,784,671.26 at the end of the previous year[3] - Total assets as of March 31, 2022, were ¥2,640,273,978.12, a decrease from ¥2,712,784,671.26 at the beginning of the year[23] - Total liabilities decreased to ¥1,357,806,726.33 from ¥1,421,226,858.64, indicating a reduction of 4.46%[23] - The total equity attributable to shareholders decreased by 0.71% to ¥1,269,448,991.73 from ¥1,278,519,957.81 at the end of the previous year[3] Shareholder Information - The company had a total of 89,114 common shareholders at the end of the reporting period[16] Earnings and Profitability - The company reported a basic earnings per share of -¥0.0165, a decrease of 22.22% from -¥0.0135 in the same period last year[3] - Basic and diluted earnings per share for Q1 2022 were both -0.0165 CNY, compared to -0.0135 CNY in Q1 2021, indicating a worsening in per-share loss[28] - Gross profit margin for Q1 2022 was approximately -9.83%, compared to a positive margin in the previous year, indicating a significant decline in profitability[25] Income and Expenses - Other income increased by 212.31% to ¥497,958.30, primarily due to technical subsidies received by a subsidiary[11] - Investment income decreased by 243.41% to -¥1,168,421.64, reflecting reduced returns from an investment in an insurance agency[12] - The company incurred financial expenses of 7,113,268.90 CNY in Q1 2022, down from 9,204,686.07 CNY in Q1 2021, representing a decrease of about 22.6%[26] Inventory and Receivables - Accounts receivable decreased to ¥279,575,176.25 from ¥300,628,962.49, reflecting a reduction of 7.02%[21] - Inventory increased to ¥334,343,135.56, up 4.01% from ¥320,051,742.32 at the beginning of the year[21] - Cash and cash equivalents at the end of Q1 2022 were ¥192,965,610.26, down 44.4% from ¥346,875,163.65 at the beginning of the year[21] - Cash and cash equivalents at the end of Q1 2022 stood at 99,681,041.57 CNY, a decrease from 88,549,436.08 CNY at the end of Q1 2021[31]